Scopus
🔓 Açık Erişim
Ceftazidime-Avibactam: A Retrospective Analysis of Multicenter Real-World Data and Factors Affecting Mortality
Infectious Diseases and Clinical Microbiology · Aralık 2025
Makale Bilgileri
DergiInfectious Diseases and Clinical Microbiology
Yayın TarihiAralık 2025
Cilt / Sayfa7 · 406-420
Scopus ID2-s2.0-105026360424
Erişim🔓 Açık Erişim
Özet
Objective: Multidrug-resistant Gram-negative bacteria cause difficult-to-treat infections associated with high mortality. Carbapenems are widely used; however, their overuse has led to the emergence of carbapenem-resistant bacteria. This study aimed to evaluate the indications, clinical and microbiological efficacy, and side effects of ceftazidime-avibactam (CAZ-AVI) and to identify factors influencing mortality, based on data from a large multicenter patient cohort in Türkiye. Materials and Methods: Patients with carbapenem-resistant but CAZ-AVI-susceptible Gram-negative bacterial infections who received CAZ-AVI treatment were retrospectively reviewed. Results: A total of 1245 patients were included. The most common indication for CAZ-AVI use was hospital-acquired pneumonia (47.8%). Klebsiella pneumoniae was the predominant pathogen (81.3%). CAZ-AVI was used as a monotherapy in 80% of cases. Clinical side effects were observed in 8 (0.64%) patients, while laboratory abnormalities occurred in 73 (5.86%). The 7-day, 14-day, and 28-day all-cause mortality rates were 13.8%, 28.9%, and 45.2%, respectively. Microbiological eradication was achieved in 82.3% of patients. Higher Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores at admission, requirement for continuous renal replacement therapy, mechanical ventilation, and elevated C-reactive protein levels were identified as independent risk factors for mortality. Conclusion: This large multicenter real-world analysis demonstrates that CAZ-AVI is an effective treatment option for severe infections with high mortality, such as those caused by carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa.
Yazarlar (22)
1
Nazlım Aktuğ Demir
2
Fatih Temoçin
ORCID: 0000-0002-4819-8242
3
Onur Ural
4
Ezgi Gülten
ORCID: 0000-0003-0248-7716
5
Ayşe Seza İnal
ORCID: 0000-0002-1182-7164
6
Cigdem Kader
7
Yasemin Ersoy
ORCID: 0000-0001-5730-6682
8
Ali Asan
ORCID: 0000-0002-8856-7356
9
Pınar Aysert-Yıldız
ORCID: 0000-0001-8737-9110
10
Şua Sümer
11
Eyüp Arslan
ORCID: 0000-0002-5490-465X
12
Yakup Gezer
ORCID: 0000-0002-1582-7313
13
Güle Çınar
ORCID: 0000-0002-7635-8848
14
Elif Mukime Sarıcaoğlu
ORCID: 0000-0002-7613-2398
15
Tuba Tatlı-Kış
ORCID: 0000-0001-6952-3748
16
Serap Özçimen
17
Barçın Öztürk
ORCID: 0000-0003-3756-8276
18
Burak Sarıkaya
ORCID: 0000-0002-0026-1927
19
Merve Türkmen
ORCID: 0009-0005-2914-7019
20
Tuba Kuruoğlu
ORCID: 0000-0003-3805-367X
21
Ceren Atasoy-Tahtasakal
ORCID: 0000-0003-0392-229X
22
Emel Yılmaz
ORCID: 0000-0002-3894-1231
Anahtar Kelimeler
carbapenem-resistant
Ceftazidime-avibactam
mortality determinants
Kurumlar
Ankara Numune Education and Research Hospital
Ankara Turkey
Ankara Üniversitesi
Ankara Turkey
Aydin Adnan Menderes University
Aydin Turkey
Bozok Üniversitesi
Yozgat Turkey
Bursa Uludağ Üniversitesi
Bursa Turkey
Bursa Yüksek lhtisas Training and Research Hospital
Bursa Turkey
Çukurova Üniversitesi Tip Fakültesi
Adana Turkey
Gazi University, Faculty of Medicine
Ankara Turkey
Inönü Üniversitesi Tip Fakültesi
Malatya Turkey
Ondokuz Mayis University, Medical School
Samsun Turkey
Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
Istanbul Turkey
Selçuk Üniversitesi
Selçuklu Turkey
Sultan 2.Abdülhamid Han Eğitim ve Araştirma Hastanesi
Uskudar Turkey
University of Health Sciences
Istanbul Turkey